Trisha Suppes, MD, PhD

Publication Details

• A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression.

  Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE, Walden J, Leverich GS, Altshuler LL, Nakelsky S, Hwang S, Mintz J, Post RM. Am J Psychiatry. 2007; 164 (8): 1242-9

  Modafinil is approved by the U.S. Food and Drug Administration for improving wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift-work sleep disorder. This study was conducted to evaluate the efficacy and safety of adjunctive modafinil in bipolar depression, which is often characterized by excessive sleepiness and fatigue.

  PubMedID: 17671288